Chinese nutritional herbs as potential alternatives for therapy-resistant breast cancer stem cells
Main Article Content
Abstract
Background: Expression status of hormone and growth factor receptors dictates treatment options for targeted chemo-endocrine therapy in breast cancer. Chemo-endocrine therapy is associated with systemic toxicity, therapy resistance and emergence of therapy-resistant cancer stem cells. These limitations emphasize identification of testable alternatives. Natural products including dietary phytochemicals and Chinese nutritional herbs exhibit low systemic toxicity, long-term human consumption and preclinical efficacy, and may function as testable therapeutic alternatives.
Objective: The main objective of this mini-review is to discuss published evidence on cellular models for clinical breast cancer subtypes, mechanistic leads for growth inhibition by nutritional herbs and applicability of drug-resistant cancer stem cell models to investigate stem cell targeting efficacy of nutritional herbs. Collectively, published evidence supports the concept that Chinese nutritional herbs may function as testable therapeutic alternatives for breast cancer.
Conclusion: The published evidence provides proof of concept that investigations on drug-resistant breast cancer stem cell models may provide mechanistic leads for effective nutritional herbs as novel therapeutic alternatives for breast cancer.
Future Prospects: Discussed evidence provides a conceptual basis for future investigations on patient-derived tumor explants and organoids. Experimental approaches using clinical tumor samples are likely to reduce extrapolation of the data for clinical relevance and translatability
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Muniraj N, Sidharth S, Sharma D: Bioactive compounds: Multi-targeting silver bullets for preventing and treating breast cancer. Cancers 2019, 11: 1563.
3. Ye L, Jia Y, Ji KE, et al: Traditional Chinese medicine in prevention and treatment of breast cancer and metastasis. Oncol. Letts 2015, 10: 1240-1250. DOI: 10.3892/ol.2015.3459.
4. Gardishar WJ, Moran MS, Abraham J: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer version 4, 2022. National Comprehensive Cancer Network. https:// www.nccn.org.
5. Telang NT: Natural bioactive agents: Testable stem cell-targeting alternatives for therapy-resistant breast cancer. Int. J. Mol. Sci. 2025, 26: 2529. DOI: 10. 3390/ijms26062529.
6. Naujokat C, Mc Kee DI: The “Big Five” phytochemicals targeting cancer stem cells: Curcumin, EGCG, sulforaphane, resveratrol and genistein. Cur. Med. Chem. 2012, 28: 4321-4342. DOI: 10.21 74/0929867327666200228110738.
7. Hong M, Tan HY, Li S, et al: Cancer stem cells: Potential targets of Chinese medicines and their active components. Int. J. Mol. Sci. 2016, 17: 993.
8. Yang Z, Zhang Q, Yu L, et al: The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple negative breast cancer. J. Ethnopharmacol. 2021, 264: 113249. DOI: 10.1016/jep.2020.113249.
9. Mukherjee B, Telang N, Wong GYC: Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellanedae tree. J. Mol. Med. 2009, 24: 253-260. DOI: 10.3892/ijmm_00000228.
10. Telang N, Nair HB, Wong GYC: Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal breast cancer. Biomed. Rep. 2019, 11: 222-229. DOI: 10.3 892/br.2019.1244.
11. Telang NT, Nair HB, Wong GYC: Anti-proliferative effects of Drynaria fortunei in a model for triple negative breast cancer. Oncol. Letts. 2025, 29: 91. DOI: 10.3892/ol.2024.14837.
12. Telang NT, Nair HB, Wong GYC: Growth inhibitory effects of a Chinese nutritional herb Viola yedoensis, in a model for triple-negative breast cancer. Arch. Breast Cancer 2025, 12: 401-409. DOI: 10.32768/abc.7581039462-817.
13. Suto A, Telang NT, Tanino H, et al: In vitro and In vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 1999, 6: 87-92. DOI: 10.1007/BFO2966913.
14. Telang NT, Li G, Sepkovic DW, et al: Anti-proliferative effects of Chinese herb Cornus officinalis in in a cell culture model for estrogen receptor positive clinical breast cancer. Mol. Med. Rep. 2012, 5: 22-28. DOI: 10.3892/mmr.2011.617.
15. Telang NT, Nair HB, Wong GYC: Growth inhibitory efficacy of Tabebuia avellandae in a model for triple negative breast cancer. Arch. Breast Cancer 2021, 8: 203-209. DOI: 10.32768/abc.202183203-209.
16. Telang NT, Nair HB, Wong GYC: Growth inhibitory efficacy of Corus officinalis in a cell culture model; for triple-negative breast cancer. Oncol. Letts. 2019, 17: 5261-5266. DOI: 10.3892/ol.201 9.10182.
17. Telang NT, Nair HB, Wong GYC: Growth inhibitory efficacy of the nutritional herb Psoralia corylifolia in a model for triple-negative breast cancer. Int. J. Funct. Nutr. 2021, 2: 8.DOI: 10.389 2/ijfn.2021.18.
18. Telang N, Nair HB, Wong GYC: Anti-proliferative and pro-apoptotic effects of Dipsacus asperoides in a cellular model for triple-negative breast cancer. Arch. Breast Cancer 2021, 9: 66-75. DOI: 10.32768/abc.20229166-75.
19. Telang N: Drug-resistant stem cell models for the hormone-responsive Luminal A breast cancer. Med. Res. Arch. 2023, 11: 3556. DOI: 10.1810 3/mra.v11i2.3556.
20. Telang N: Stem cell targeting natural products for therapy-resistant triple-negative breast cancer. Med. Res. Arch. 2025, 13: 6584. DOI: 10.18103//m ra.v13i6.6584.
21. Girdler F, Brotherick I: The estrogen receptors (ER-α and ER-β) and their role in breast cancer: A review. Breast 2000, 9: 194-200. DOI: 10.1054/br st.2000.0203.
22. Ranganathan P, Nadig N, Nambiar S: Non-canonical estrogen signaling in endocrine resistance. Front. Endocrinol. 2019, 18: 708. DOI: 10.3389/fe ndo.2019.00708.
23. Kuipper GG, Lemmen JG, Carlson B, et al: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 1998, 139: 4252-4263. DOI: 10.1210/endo.139.10.6216.
24. Kostelac D, Rechkemmer G, Breviba K, Phytoestrogens modulate binding response of estrogen receptor estrogen receptors α and β to the estrogen response element. J. Agric. Food Chem. 2003, 51: 7632-7635. DOI: 10.1021/jfo34427b
25. Das GM, Oturkar CC, Park J, et al: synergistic effect of tamoxifen and doxorubicin on a novel estrogen receptor β-p53-p73 axis: A new therapeutic strategy against triple-negative breast cancer. Cancer Res. 2025, 85 (8_Suppl_2) : Abstract # LB005. DOI: 10.1158/1538-7445.AM2025-LB005.
26. Dharwal N, Rathore D, Shukla N, Dave HV: Increased TGF-β signaling during anti-estrogen therapy in triple-negative breast cancer cells. J. Steroid Biochem. Mol. Biol. 2025, 257: 106934. DOI: 10.1016/j.jsbmb.2025.106934.
27. Berman TA, Ben-Arye E, Kienle GS, Master V, Huston A, Paller CJ: Integrating botanicals into oncology care: Consideration of FDA regulation of botanical products and botanical clinical trials. Clin. Cancer Res. 31: 1566-1572, 2025.
28. Bruna A, Rueda OM, Greenwood W, et al: A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anti-cancer compounds. Cell 2016, 167: 260-274, DOI: 10.101 6/j.cell.2016.08.041.
29. Pan B, Zhaou D, Liu, t al: Breast cancer organoids from malignant plural effusion-derived tumor cells as an individualized medicine platform. In vitro Cell Dev Biol. Anim.212, 57: 510-518. DOI: 10.1007/s11626-021-00563-9.